Literature DB >> 20133487

Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Eberhard Ritz, René Wenzel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20133487      PMCID： PMC4473251          DOI： 10.1681/ASN.2010010047

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  21 in total

Review 1.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Authors:  Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn
Journal:  Circulation       Date:  2003-12-09       Impact factor: 29.690

2.  Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention.

Authors:  Yuqiang Ge; Alan Bagnall; Peter K Stricklett; Kevin Strait; David J Webb; Yuri Kotelevtsev; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2006-07-25

3.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

4.  Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.

Authors:  J Smolander; B Vogt; M Maillard; C Zweiacker; T Littke; T Hengelage; M Burnier
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

5.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

6.  Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons.

Authors:  Takako Makita; Henry M Sucov; Cheryl E Gariepy; Masashi Yanagisawa; David D Ginty
Journal:  Nature       Date:  2008-04-10       Impact factor: 49.962

7.  Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.

Authors:  Neeraj Dhaun; Iain M Macintyre; Vanessa Melville; Pajaree Lilitkarntakul; Neil R Johnston; Jane Goddard; David J Webb
Journal:  Hypertension       Date:  2009-06-08       Impact factor: 10.190

8.  Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

Authors:  Volker Vallon; Edith Hummler; Timo Rieg; Oleh Pochynyuk; Vladislav Bugaj; Jana Schroth; Georges Dechenes; Bernard Rossier; Robyn Cunard; James Stockand
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121

9.  The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Authors:  H J Lambers Heerspink; R Agarwal; D W Coyne; H-H Parving; E Ritz; G Remuzzi; P Audhya; M J Amdahl; D L Andress; D de Zeeuw
Journal:  Am J Nephrol       Date:  2009-06-15       Impact factor: 3.754

10.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121
View more
  4 in total

Review 1.  Hypertension in 2010: Blood pressure and the kidney.

Authors:  Luis M Ruilope
Journal:  Nat Rev Nephrol       Date:  2011-02       Impact factor: 28.314

Review 2.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

Review 3.  Limitations and future treatment options in type 2 diabetes with renal impairment.

Authors:  Eberhard Ritz
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

4.  Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.

Authors:  Neeraj Dhaun; Jale Yuzugulen; Robert A Kimmitt; Elizabeth G Wood; Pajaree Chariyavilaskul; Iain M MacIntyre; Jane Goddard; David J Webb; Roger Corder
Journal:  J Am Heart Assoc       Date:  2015-03-23       Impact factor: 5.501
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.